Neuren receives $1 million R&D Tax Incentive

Melbourne, Australia, 4 April 2017: Neuren Pharmaceuticals (ASX: NEU) today received cash of approximately $1 million under the Australian R&D Tax Incentive program. The incentive is in respect of Neuren’s research and development expenditure for the year ended 31 December 2016.

For more information, please contact:
Jon Pilcher, CFO & Company Secretary: jipilcher@neurenpharma.com ; +61 438 422 271

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for neurodevelopmental disorders, neurodegenerative diseases and acute brain injury. Neuren presently has a clinical stage molecule, trofinetide in Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development.

Forward-looking Statements
This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.